{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:52:32Z","timestamp":1792723952273,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["NCT02164513"],"award-info":[{"award-number":["NCT02164513"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["CTT116855"],"award-info":[{"award-number":["CTT116855"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["HO-17-17596"],"award-info":[{"award-number":["HO-17-17596"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.rmed.2024.107694","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T06:49:45Z","timestamp":1717570185000},"page":"107694","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The long-term clinical and economic benefits of treating advanced COPD patients with single-inhaler triple therapy in Quebec, Canada \u2013 The IMPACT trial"],"prefix":"10.1016","volume":"231","author":[{"given":"Nancy A.","family":"Risebrough","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mursleen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5737-3156","authenticated-orcid":false,"given":"Kerigo","family":"Ndirangu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhvani","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afisi S.","family":"Ismaila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.rmed.2024.107694_bib2","first-page":"319","article-title":"The burden of illness in patients with moderate to severe chronic obstructive pulmonary disease in Canada","volume":"19","author":"Maleki-Yazdi","year":"2012","journal-title":"Can. Respir. J. J. Can. Thorac. Soc."},{"key":"10.1016\/j.rmed.2024.107694_bib3","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1186\/s13104-015-1427-y","article-title":"Clinical, humanistic, and economic burden of chronic obstructive pulmonary disease (COPD) in Canada: a systematic review","volume":"8","author":"Dang-Tan","year":"2015","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.rmed.2024.107694_bib4","author":"Theriault"},{"key":"10.1016\/j.rmed.2024.107694_bib5","series-title":"Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease","year":"2023"},{"issue":"4","key":"10.1016\/j.rmed.2024.107694_bib6","first-page":"210","article-title":"Canadian thoracic society clinical practice guideline on pharmacotherapy in patients with COPD \u2013 2019 update of evidence","volume":"3","author":"Bourbeau","year":"2019","journal-title":"Can. J. Respir. Crit. Care Sleep Med."},{"issue":"18","key":"10.1016\/j.rmed.2024.107694_bib8","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.rmed.2024.107694_bib10","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","article-title":"Susceptibility to exacerbation in chronic obstructive pulmonary disease","volume":"363","author":"Hurst","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.rmed.2024.107694_bib11","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2213-2600(17)30207-2","article-title":"Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort","volume":"5","author":"Han","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2024.107694_bib12","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.2147\/COPD.S216072","article-title":"Cost-effectiveness of once-daily single-inhaler triple therapy in COPD: the IMPACT trial","volume":"14","author":"Ismaila","year":"2019","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.rmed.2024.107694_bib13","article-title":"Cost-effectiveness analysis of a single-inhaler triple therapy for patients with advanced chronic obstructive pulmonary disease (COPD) using the FULFIL trial: a UK perspective","volume":"X 1","author":"Schroeder","year":"2019","journal-title":"Respir. Med."},{"issue":"5","key":"10.1016\/j.rmed.2024.107694_bib14","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1177\/0272989X12454941","article-title":"Conceptualizing a model: a report of the ISPOR-SMDM modeling Good Research practices Task force-2","volume":"32","author":"Roberts","year":"2012","journal-title":"Med. Decis. Making : an international journal of the Society for Medical Decision Making"},{"issue":"4","key":"10.1016\/j.rmed.2024.107694_bib15","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/0272989X16653118","article-title":"Development of the Galaxy chronic obstructive pulmonary disease (COPD) model using data from ECLIPSE: internal validation of a linked-equations cohort model","volume":"37","author":"Briggs","year":"2017","journal-title":"Med. Decis. Making"},{"issue":"7","key":"10.1016\/j.rmed.2024.107694_bib16","doi-asserted-by":"crossref","first-page":"A560","DOI":"10.1016\/j.jval.2014.08.1852","article-title":"Validating a model to predict disease progression outcomes in patients with COPD","volume":"17","author":"Risebrough","year":"2014","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.rmed.2024.107694_bib17","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jval.2016.10.016","article-title":"External validation of health economic decision models for chronic obstructive pulmonary disease (COPD): report of the third COPD modeling meeting","volume":"20","author":"Hoogendoorn","year":"2017","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.rmed.2024.107694_bib18","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/0272989X15610781","article-title":"Statistical modeling of disease progression for chronic obstructive pulmonary disease using data from the ECLIPSE study","volume":"37","author":"Exuzides","year":"2017","journal-title":"Med. Decis. Making"},{"key":"10.1016\/j.rmed.2024.107694_bib19","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.rmed.2018.10.024","article-title":"Cost-effectiveness of umeclidinium as add-on to ICS\/LABA therapy in COPD: a UK perspective","volume":"145","author":"Driessen","year":"2018","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2024.107694_bib20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12962-018-0101-3","article-title":"Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective, Cost Eff","volume":"16","author":"Shah","year":"2018","journal-title":"Resour. Alloc."},{"issue":"4","key":"10.1016\/j.rmed.2024.107694_bib21","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1177\/0272989X16662009","article-title":"Development of a conceptual model of disease progression for use in economic modeling of chronic obstructive pulmonary disease","volume":"37","author":"Tabberer","year":"2017","journal-title":"Med. Decis. Making"},{"issue":"3","key":"10.1016\/j.rmed.2024.107694_bib22","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1183\/09031936.00125612","article-title":"Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification","volume":"42","author":"Jones","year":"2013","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.rmed.2024.107694_bib23","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jval.2010.09.011","article-title":"Predicting EQ-5D values using the SGRQ","volume":"14","author":"Starkie","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.rmed.2024.107694_bib27","series-title":"Guidance document for submitting a request to l'Institut national d\u2019excellence en sant\u00e9 et en services sociaux (INESSS)","year":"2017"},{"issue":"7","key":"10.1016\/j.rmed.2024.107694_bib28","doi-asserted-by":"crossref","first-page":"A488","DOI":"10.1016\/j.jval.2016.09.821","article-title":"Cadth's $50,000 cost-effectiveness threshold: fact or fiction?","volume":"19","author":"Griffiths","year":"2016","journal-title":"Value Health"},{"issue":"Suppl 4","key":"10.1016\/j.rmed.2024.107694_bib29","first-page":"A232","article-title":"P240 Evaluating patient preferences of maintenance therapy for the treatment of chronic obstructive pulmonary disease in the UK: a discrete choice experiment","volume":"73","author":"Schroeder","year":"2018","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.rmed.2024.107694_bib30","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1183\/23120541.00333-2021","article-title":"Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial","volume":"8","author":"Martin","year":"2022","journal-title":"ERJ Open Res"},{"issue":"Suppl 2","key":"10.1016\/j.rmed.2024.107694_bib31","first-page":"A66","article-title":"S104 Cost-effectiveness of triple therapy with budesonide\/glycopyrronium\/formoterol fumarate versus dual therapies in moderate-to-very severe COPD in the United Kingdom: analysis based on the KRONOS study","volume":"76","author":"de Nigris","year":"2021","journal-title":"Thorax"},{"issue":"Suppl 1","key":"10.1016\/j.rmed.2024.107694_bib32","first-page":"S46","article-title":"POSA67 Cost-effectiveness of triple therapy with budesonide\/glycopyrronium\/formoterol fumarate vs dual therapies in moderate-to-very severe COPD: United Kingdom analysis using the ETHOS study","volume":"25","author":"de Nigris","year":"2022","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.rmed.2024.107694_bib33","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1183\/09031936.00111707","article-title":"Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE)","volume":"31","author":"Vestbo","year":"2008","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2024.107694_bib34","series-title":"Care in Canadian ICUs","year":"2016"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611124001689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611124001689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T05:16:43Z","timestamp":1778563003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611124001689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":28,"alternative-id":["S0954611124001689"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2024.107694","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The long-term clinical and economic benefits of treating advanced COPD patients with single-inhaler triple therapy in Quebec, Canada \u2013 The IMPACT trial","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2024.107694","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107694"}}